United States - English - NLM (National Library of Medicine)

seqirus inc. - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (propiolactone inactivated) (unii: v8pc20ubcn) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:wlsrj8jc6s) - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (propiolactone inactivated) 15 ug in 0.5 ml

United States - English - NLM (National Library of Medicine)

seqirus pty ltd - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) (unii: 9jwn7vdq7n) (influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:u6c4gj6wzg), influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) (unii: a5wli8wk8a) (influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:37h6eg2naq), influenza b vi - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 5 years of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated backg

United States - English - NLM (National Library of Medicine)

seqirus pty ltd - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) (unii: 9jwn7vdq7n) (influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:u6c4gj6wzg), influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) (unii: a5wli8wk8a) (influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:37h6eg2naq), influenza b vi - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - afluria® is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and type b present in the vaccine. afluria is approved for use in persons 5 years of age and older. afluria is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy category b: a reproductive and developmental toxicity study has been performed in female rats at a dose approximately 265 times the human dose (on a mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to afluria. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, afluria should be given to a pregnant woman only if clearly needed. in the reproductive and developmental toxicity study, the effect

United States - English - NLM (National Library of Medicine)

catalent belgium sa - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (propiolactone inactivated) (unii: v8pc20ubcn) (influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:wlsrj8jc6s) - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) antigen (propiolactone inactivated) 15 ug in 0.5 ml

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: singapore genebio, inc.; distributor: endure medical, inc. - doxycycline (as hyclate) - capsule - 100mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: singapore genebio, inc.; distributor: endure medical, inc. - cardiomide - sustained release tablet - 1.5mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: singapore genebio, inc.; distributor: endure medical, inc. - methyl salicylate , menthol , eugenol - cream - 102 mg/ 54.40 mg/ 13.60 mg per g

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: singapore genebio, inc.; distributor: endure medical inc. - sildenafil (as citrate) - film-coated tablet - 50mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: singapore genebio, inc.; distributor: endure medical, inc. - sildenafil (as citrate) - film-coated tablet - 100mg

Philippines - English - FDA (Food And Drug Administration)

phil. pharmawealth, inc.; distributor: singapore genebio, inc. - triamcinolone acetonide - suspension for injection (i.m./i.a./i.d.) - 40 mg/ ml